A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

Change from Baseline in Hemoglobin A1c (HbA1c)

Time frame: Baseline, Week 52

Change from Baseline in Number of Manual Insulin Boluses

Time frame: Baseline, Week 52

Rate of Clinically Significant Hypoglycemic Events

Time frame: Baseline through Week 52

Change from Baseline in Fasting C-Peptide

Time frame: Baseline, Week 52

Change from Baseline in Height

Time frame: Baseline, Week 52

Change from Baseline in Mean Total Daily Insulin Dose

Measured during the two weeks prior to the assessment

Time frame: Baseline, Week 52

Change from Baseline in Short Form 36 Version 2 Health Survey, Acute (SF-36v2)

Time frame: Baseline, Week 52

Change from Baseline in Matsuda Index

Time frame: Baseline, Week 52

Pharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib

Time frame: Predose through Week 16